HPV Vaccines

Human Papillomavirus (HPV) vaccine is an inactivated (not live) vaccine which protects against four major types of HPV.

These include two types that cause about 70% of cervical cancer and two types that cause about 90% of genital warts. HPV vaccine can prevent most genital warts and most cases of cervical cancer. Protection from HPV vaccine is expected to be long-lasting. But vaccinated women still need cervical cancer screening because the vaccine does not protect against all HPV types that cause cervical cancer.

Routine Vaccination

  • HPV vaccine is routinely recommended for girls 11 and 12 years of age
  • The HPV4 vaccine (the type recommended for prevention of genital warts in girls) may also be given in three doses to boys aged 9 to 26.

  • Advances in HPV Vaccine
  • HPV Vaccines for Men
  • HPV Vaccine risks and controversies
  • HPV Vaccine for Women
  • Global HPV Vaccine Market Analysis

Related Conference of HPV Vaccines

July 27-28, 2017

International Vaccines Congress

Chicago, USA
August 21-22, 2017

17th International Conference on Children Vaccines

Birmingham, UK
September 18-19, 2017

20th Global Summit & Expo on Vaccines & Immunization

(10 Plenary Forums-1Event) Houston, USA
July 27-28, 2017

19th International Vaccines Congress

Chicago, USA
October 05-07, 2017

World Vaccines and Immunization Congress

Osaka, Japan
November 30-December 01, 2017

23rd Global Vaccines & Vaccination Summit

Dubai, UAE

HPV Vaccines Conference Speakers

Recommended Sessions

Related Journals

Are you interested in